studies

la/mBC - HR-positive - 2nd line (L2), alpelisib based treatment vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsSOLAR-1 (patients with PIK3CA mutant status), 2019 0.86 [0.64; 1.15] 0.86[0.64; 1.15]SOLAR-1 (patients with PIK3CA mutant status), 201910%341NAnot evaluable progression or deaths (PFS)detailed resultsSOLAR-1 (patients with PIK3CA mutant status), 2019 0.65 [0.50; 0.85] SOLAR-1 (patients without PIK3CA mutant status), 2019 0.85 [0.58; 1.25] 0.72[0.56; 0.92]SOLAR-1 (patients with PIK3CA mutant status), 2019, SOLAR-1 (patients without PIK3CA mutant status), 2019221%572lownot evaluable CBRdetailed resultsSOLAR-1 (patients with PIK3CA mutant status), 2019 1.93 [1.25; 2.97] 1.93[1.25; 2.97]SOLAR-1 (patients with PIK3CA mutant status), 201910%341NAnot evaluable objective responses (ORR)detailed resultsSOLAR-1 (patients with PIK3CA mutant status), 2019 2.47 [1.41; 4.34] 2.47[1.41; 4.34]SOLAR-1 (patients with PIK3CA mutant status), 201910%341NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-05-10 16:25 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 353,358,359 - treatments: 1409,717,1410,1418

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons